{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yuan L"],"funding":["Beijing Natural Science Foundation Project","Guangdong Basic and Applied Basic Research Foundation","Sanming Project of Medicine in Shenzhen Nanshan","CAMS Innovation Fund for Medical Sciences","Science and Technology Projects in Guangzhou","Shenzhen Science and Technology Program"],"pagination":["357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12937623"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(4)"],"pubmed_abstract":["Influenza's pandemic threat is driven by antigenic drift, which limits the efficacy of conventional vaccines. To address this challenge, we established a clinical serum-anchored computational design pipeline for a broad-spectrum multi-epitope mRNA vaccine (MEMV), bridging the gap between pure in silico design and clinical applicability. Using 36 longitudinal sera (d0/d28/d365) from 12 well-characterized human cohorts (6 vaccine recipients and 6 influenza patients) and high-density antibody-peptide microarrays, we empirically identified 12 immunodominant B-cell linear epitopes from the nucleoprotein (NP) of influenza A (H1N1/H3N2) and B viruses. These experimentally validated epitopes were combined with in silico-predicted conserved helper T-lymphocyte (HTL)/cytotoxic T-lymphocyte (CTL) epi"],"journal":["Biology"],"pubmed_title":["Clinical Serum-Anchored Computational Design Pipeline for a Broad-Spectrum Influenza Multi-Epitope mRNA Vaccine."],"pmcid":["PMC12937623"],"funding_grant_id":["L254023","2022-I2M-1-021;2023-I2M-2-001","2024A04J4015","SZSM202103008","No. L242036","KCXFZ20211020172545006; KQTD20200820145822023; ZDSYS20230626091203007","2023A1515011767"],"pubmed_authors":["Yan M","Bi R","Yuan L","Wen S","Luo H","Zhao Y","Song J","Li W","Li X","Bai T","Li Y","Chen Y","Ouyang Z","Shu Y","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Serum-Anchored Computational Design Pipeline for a Broad-Spectrum Influenza Multi-Epitope mRNA Vaccine.","description":"Influenza's pandemic threat is driven by antigenic drift, which limits the efficacy of conventional vaccines. To address this challenge, we established a clinical serum-anchored computational design pipeline for a broad-spectrum multi-epitope mRNA vaccine (MEMV), bridging the gap between pure in silico design and clinical applicability. Using 36 longitudinal sera (d0/d28/d365) from 12 well-characterized human cohorts (6 vaccine recipients and 6 influenza patients) and high-density antibody-peptide microarrays, we empirically identified 12 immunodominant B-cell linear epitopes from the nucleoprotein (NP) of influenza A (H1N1/H3N2) and B viruses. These experimentally validated epitopes were combined with in silico-predicted conserved helper T-lymphocyte (HTL)/cytotoxic T-lymphocyte (CTL) epi","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-11T03:16:26.018Z","creation":"2026-07-11T03:11:44.167Z"},"accession":"S-EPMC12937623","cross_references":{"pubmed":["41744666"],"doi":["10.3390/biology15040357"]}}